Melittin-incorporated nanomedicines for enhanced cancer immunotherapy,Journal of Controlled Release

当前位置： X-MOL 学术 › J. Control. Release › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
Journal of Controlled Release ( IF 10.5 ) Pub Date : 2024-09-13 , DOI: 10.1016/j.jconrel.2024.08.047
Xuefeng Duan ₁ , Haoyang Zou ₂ , Jiazhen Yang ₂ , Shixian Liu ₃ , Tianmin Xu ₁ , Jianxun Ding ₂

Affiliation

Immunotherapy is a rapidly developing and effective strategy for cancer therapy. Among various immunotherapy approaches, peptides have garnered significant attention due to their potent immunomodulatory effects. In particular, melittin emerged as a promising candidate to enhance cancer immunotherapy by inducing immunogenic cell death, promoting the maturation of antigen-presenting cells, activating T cells, enhancing the infiltration and cytotoxicity of effector lymphocytes, and modulating macrophage phenotypes for relieving immunosuppression. However, the clinical application of melittin is limited by poor targeting and systemic toxicity. To overcome these challenges, melittin has been incorporated into biomaterials and related nanotechnologies, resulting in extended circulation time in vivo, improved targeting, reduced adverse effects, and enhanced anti-cancer immunological action. This review provides an in-depth analysis of the immunomodulatory effects of melittin-incorporated nanomedicines and examines their development and challenges for clinical cancer immunotherapy.

中文翻译：

掺入蜂毒肽的纳米药物，用于增强癌症免疫治疗

免疫疗法是一种快速发展且有效的癌症治疗策略。在各种免疫治疗方法中，肽因其强大的免疫调节作用而受到广泛关注。特别是，蜂毒肽通过诱导免疫原性细胞死亡、促进抗原呈递细胞成熟、激活 T 细胞、增强效应淋巴细胞的浸润和细胞毒性以及调节巨噬细胞表型以缓解免疫抑制，成为增强癌症免疫治疗的有前途的候选药物。然而，蜂毒肽的临床应用受到靶向性差和全身毒性的限制。为了克服这些挑战，蜂毒肽已被纳入生物材料和相关纳米技术中，从而延长了体内循环时间、改进了靶向性、减少了不良反应并增强了抗癌免疫作用。本文深入分析了蜂毒肽掺入纳米药物的免疫调节作用，并探讨了其发展和临床癌症免疫治疗面临的挑战。

更新日期：2024-09-13

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南